MultiOmic Health and Alloy Therapeutics Partner to Develop Precision Kidney Medicines Using AI
• MultiOmic Health and Alloy Therapeutics have signed an agreement to jointly discover and develop first-in-class renal tissue-targeting drugs for chronic kidney conditions using AI-enabled precision medicine approaches.
• The collaboration will leverage MultiOmic's ability to identify fast-progressing patient subpopulations and novel drug targets, while Alloy will deploy its bispecific antibody and genetic medicine platforms to engineer kidney-specific therapeutics.
• A new asset-centric company, tentatively called "RenalDevCo," will be established through Alloy's venture studio to commercialize the therapies, with both companies receiving equity stakes and milestone payments.
© Copyright 2025. All Rights Reserved by MedPath